All Updates

All Updates

icon
Filter
Partnerships
Sidekick Health and Eli Lilly partner to launch DTx for breast cancer
Preventive Healthcare
Jun 16, 2022
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Product updates
Microsoft launches Copilot Actions for workplace automation
Foundation Models
Yesterday
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Preventive Healthcare

Preventive Healthcare

Jun 16, 2022

Sidekick Health and Eli Lilly partner to launch DTx for breast cancer

Partnerships

  • Digital therapeutics (DTx) startup Sidekick Health and pharmaceutical company Eli Lilly have partnered to launch a DTx product for patients diagnosed with breast cancer. The digital product will offer a personalized treatment plan with behavioral modifications to improve wellbeing and support drug treatment adherence and side effects management.  

  • The DTx will be tailored for patients treated with Lilly’s breast cancer medication including Verzenio, a CDK 4/6 inhibitor, which is expected to launch in Germany in July 2022. 

<ul><li> The latest collaboration comes hot on the heels of Sidekick’s partnership with Pfizer to develop a DTx solution targeting treatment adherence for atopic dermatitis or eczema. The company planned to announce three collaborations in the upcoming months following its funding round in May 2022 .</ul>

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.